Table 3.
Patient-level adverse events related to QTc prolongation.
| Randomized arm | ECG QTc ≥60 ms change from baselinea,b | ECG QTc >500 msa,b | Total QTc-related adverse eventsb | Total participants |
|---|---|---|---|---|
| Ascorbic acid + folic acid | 2 (2.5) | 0 (0) | 2 (2.5) | 80 |
| Hydroxychloroquine + folic acid | 19 (29.2) | 2 (3.1) | 19 (29.2) | 65 |
| Hydroxychloroquine + azithromycin | 7 (9.5) | 0 (0) | 7 (9.5) | 74 |
| Total | 28 (12.7) | 2 (0.9) | 28 (12.8) | 219 |
aColumns are not mutually exclusive (all ECG QTc >500 ms were also ≥60 ms change from baseline).
bValues are the number of participants followed by the percent of total patients in the row within parentheses.